2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors
Graphic
References (25)
- et al.
J. Biol. Chem.
(1991) - et al.
Annu. Rep. Med. Chem.
(1995) - et al.
Annu. Rep. Med. Chem.
(1997) - et al.
Med. Res. Rev.
(1996) - et al.
- et al.
- et al.
- et al.
J. Pharmacol. Exp. Ther.
(1990) - et al.
- et al.
J. Med. Chem.
(1996)
Cited by (151)
Cyclooxygenase
2023, Metalloenzymes: From Bench to BedsideNucleophilic Aromatic Substitution of 5-Bromo-1,2,3-triazines with Phenols
2022, Journal of Organic ChemistryPyridine ring as an important scaffold in anticancer drugs
2022, Recent Developments in the Synthesis and Applications of PyridinesSynthesis of medicinally important heterocycles inside the nanoreactors built-in nonconventional reaction media
2020, Green Approaches in Medicinal Chemistry for Sustainable Drug DesignSynthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents
2019, European Journal of Medicinal ChemistryCitation Excerpt :On the other hand, inhibition of COX-2 isozyme accounts for the therapeutic benefits of NSAIDs, since COX-2 induces inflammatory conditions and is involved in the production of prostaglandins mediating pain [5]. Several highly selective COX-2 inhibitors (coxibs) have been reported and marketed [6], including celecoxib [7] and etoricoxib [8] (Fig. 1). Even though these drugs produce less ulceration than conventional NSAIDs, coxibs still produce significant gastric and cardiovascular side effects due to the decrease in the protective prostacyclin (PGI2) production [9,10].
Copyright © 1998 Published by Elsevier Ltd.